Filana Therapeutics Inc (FLNA)

[tootalljones]

great post. and I have no quarrel with anavex and a 4 symbol thing and have made a ton of money off those letters. Quite the opposite. The sharpest commentator on that message board by a wide gap is doc238, who has owned both stocks from time to time and provides astute comments.

Here is his quick uptake on the SAVA results. He is quite remarkable and always willing to change his views if he rethinks a point or new information comes to light. I call him the "Gaming Doc (or) the Gambling Doc" but he is much more than that. He may well be God who comes to visit CNS message boards from time to time.


Doc328

01/24/23 12:23 PM

#399769 RE: tootalljones #399736

why do you say Remi is pulling tricks? thanks in advance..



I don't think the results are terrible and the price drop under 30 is probably overkill. The data seems overinterpreted in some analysis, under in others. I see two issues, the first prompting my obfuscation remark. Responder results like those below are difficult to fully interpret due to incomplete nature of the population (they left out saying how bad the worse group did) -- just how well responders did and hoe ok stable patients did. Everyone wants to show the improvement while ignoring the other patients. This is the type of data Anavex also shows with responder analysis without accounting for the whole group (including those who do worse). That's why regulatory agencies like mean comparisons against a placebo (or another drug). Their biomarker data looked good.

47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patients declined less than 5 points on ADAS-Cog over 1 year, and this group declined by 2.5 points.

what about the other 30% of patients??

The second issue is more of a concern for their future Phase 3 results. The two large SAVA studies enroll MMSE 16-27 (or CDR 0.5 to 2)--- that's a lot of Moderate AD (just shown by their new data not to respond) potentially diluting the potential success in mild AD patients. IMO, they were wrong to have an MMSE range so low in both studies and may pay the price when the analysis of the controlled studies occur.
Congrats on selling SAVA at the right time. I have a small position did covered calls with some. That should reduce the basis a bit more. I sold some short puts strike 25 today and will exercise if they expire ITM.